Boston Scientific Corporation $BSX Stock Holdings Raised by Adell Harriman & Carpenter Inc.

Adell Harriman & Carpenter Inc. lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 24.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 56,486 shares of the medical equipment provider’s stock after buying an additional 11,007 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in Boston Scientific were worth $5,515,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Steph & Co. acquired a new position in shares of Boston Scientific in the 3rd quarter worth approximately $25,000. Financial Consulate Inc. bought a new stake in Boston Scientific during the third quarter valued at $25,000. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $26,000. United Community Bank boosted its holdings in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares during the period. Finally, Kilter Group LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $30,000. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Wells Fargo & Company raised their target price on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Morgan Stanley boosted their price objective on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Finally, Canaccord Genuity Group lowered their price target on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $123.26.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 191,105 shares of company stock worth $18,067,697. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $91.56 on Wednesday. The stock has a market cap of $135.73 billion, a P/E ratio of 48.96, a P/E/G ratio of 1.63 and a beta of 0.67. The firm’s 50-day simple moving average is $94.89 and its 200 day simple moving average is $99.29. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.